People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. | — | Biotechnology | Series B | $29.0M | $978.3M | 2020 |
| Quellis Biosciences, Inc. | — | Biotechnology | Series A | $13.1M | $29.7M | 2018 |
| Viridian, LLC | — | Biotechnology | Seed | $1.1M | $51.1M | 2018 |
Tomas Kiselak at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tomas Kiselak on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Violin | 3 | 5 |
| Peter Harwin | 3 | 4 |
| Frederick Callori | 1 | 4 |
| Christopher Garabedian | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.